The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment
Abstract
:1. Introduction
2. CD30 in Disease
2.1. Hodgkin Lymphoma and CD30
2.2. Embryonal Carcinoma and CD30
2.3. Anaplastic Large Cell Lymphoma (ALCL) and CD30
2.3.1. ALK-Positive (ALK+) Anaplastic Large Cell Lymphoma (ALCL)
2.3.2. ALK-Negative Anaplastic Large Cell Lymphoma (ALCL)
2.4. Mycosis Fungoides and CD30
3. Therapeutic Approaches Based on CD30
3.1. Brentuximab Vedotin
3.2. Bispecific Antibodies (bsAbs)
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Younes, A.; Carbone, A. Clinicopathologic and Molecular Features of Hodgkin Lymphoma. Cancer Biol. 2003, 2, 500–507. [Google Scholar] [CrossRef] [Green Version]
- Fonatsch, C.; Latza, U.; Dürkop, H.; Rieder, H.; Stein, H. Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics 1992, 14, 825–826. Available online: https://www.sciencedirect.com/science/article/pii/S0888754305802034 (accessed on 15 May 2023). [CrossRef] [PubMed]
- Smith, C.A.; Gruss, H.J.; Davis, T.; Anderson, D.; Farrah, T.; Baker, E.; Sutherland, G.R.; Brannan, C.I.; Copeland, N.G.; Jenkins, N.A. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993, 73, 1349–1360. [Google Scholar] [CrossRef] [PubMed]
- Berney, D.M.; Shamash, J.; Pieroni, K.; Oliver, R.T.D. Loss of CD30 expression in metastatic embryonal carcinoma: The effects of chemotherapy? Histopathology 2001, 39, 382–385. [Google Scholar] [CrossRef] [PubMed]
- Bowen, M.A.; Olsen, K.J.; Cheng, L.; Avila, D.; Podack, E.R. Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J. Immunol. 1993, 151, 5896–5906. [Google Scholar] [CrossRef]
- Ranjitha, V.N.; Khemani, R.; Rao, B.V.; Fonseca, D.; Murthy, S.S.; Giridhar, A.; Jayakarthik, Y.; Sharma, R.; Raju, K.V.V.N.; Rao, T.S.; et al. The core four—A panel of immunohistochemistry markers to diagnose and subtype testicular germ cell tumors. Urol Ann. 2022, 14, 21–26. [Google Scholar] [CrossRef]
- Buchan, S.L.; Al-Shamkhani, A. Distinct Motifs in the Intracellular Domain of Human CD30 Differentially Activate Canonical and Alternative Transcription Factor NF-κB Signaling. PLoS ONE 2012, 7, e45244. [Google Scholar] [CrossRef] [Green Version]
- Muta, H.; Boise, L.H.; Fang, L.; Podack, E.R. CD30 Signals Integrate Expression of Cytotoxic Effector Molecules, Lymphocyte Trafficking Signals, and Signals for Proliferation and Apoptosis1. J. Immunol. 2000, 165, 5105–5111. [Google Scholar] [CrossRef]
- Telford, W.G.; Nam, S.Y.; Podack, E.R.; Miller, R.A. CD30-Regulated Apoptosis in Murine CD8 T Cells after Cessation of TCR Signals. Cell Immunol. 1997, 182, 125–136. Available online: https://www.sciencedirect.com/science/article/pii/S0008874997912284 (accessed on 18 May 2023). [CrossRef]
- Chen, L.; Wang, M.; Fan, H.; Hu, F.; Liu, T. Comparison of pediatric and adult lymphomas involving the mediastinum characterized by distinctive clinicopathological and radiological features. Sci. Rep. 2017, 7, 2577. [Google Scholar] [CrossRef] [Green Version]
- Simonetti, S.; Muñoz, N.P.; Vivancos, J.L.; Sitjes, L.S.; Pérez, J.C.H.; Bohorquez, N.L.; Maestre Alcacer, J.A.; de García, I.K.; Carrasco García, M.Á. IgG4-related Disease in Thymus. A Very Rare Case of Chronic Fibrosis Mimicking Sarcoidosis. Tumori J. 2017, 103 (Suppl. S1), S19–S24. [Google Scholar] [CrossRef]
- Johnson, P.W.M., IV. Masses in the mediastinum: Primary mediastinal lymphoma and intermediate types. Hematol. Oncol. 2015, 33, 29–32. [Google Scholar] [CrossRef]
- Maeshima, A.M.; Taniguchi, H.; Suzuki, T.; Yuda, S.; Toyoda, K.; Yamauchi, N.; Makita, S.; Fukuhara, S.; Munakata, W.; Maruyama, D.; et al. Distribution of malignant lymphomas in the anterior mediastinum: A single-institution study of 76 cases in Japan, 1997–2016. Int. J. Hematol. 2017, 106, 675–680. [Google Scholar] [CrossRef] [PubMed]
- Duwe, B.V.; Sterman, D.H.; Musani, A.I. Tumors of the Mediastinum. Chest 2005, 128, 2893–2909. [Google Scholar] [CrossRef] [PubMed]
- Marchevsky, A.; Marx, A.; Ströbel, P.; Suster, S.; Venuta, F.; Marino, M.; Yousem, S.; Zakowski, M. Policies and Reporting Guidelines for Small Biopsy Specimens of Mediastinal Masses. J. Thorac. Oncol. 2011, 6, S1724–S1729. [Google Scholar] [CrossRef] [Green Version]
- Jevremovic, D.; Roden, A.C.; Ketterling, R.P.; Kurtin, P.J.; McPhail, E.D. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma. Am. J. Clin. Pathol. 2016, 145, 180–190. [Google Scholar] [CrossRef]
- Menter, T.; Gasser, A.; Juskevicius, D.; Dirnhofer, S.; Tzankov, A. Diagnostic Utility of the Germinal Center–associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms. Appl. Immunohistochem. Mol. Morphol. 2015, 23, 491–498. Available online: https://journals.lww.com/appliedimmunohist/Fulltext/2015/08000/Diagnostic_Utility_of_the_Germinal.3.aspx (accessed on 19 May 2023). [CrossRef]
- Alduaij, W.; Hilton, L.K.; Al Moosawi, M.; Ben-Neriah, S.; Meissner, B.; Boyle, M.; Mekwunye, K.; Scott, D.W.; Leitch, H.A.; Craig, J.W. Concurrent Composite Lymphomas Collectively Bearing Three Diagnostic Entities of Shared Clonal Origin. Hemasphere 2022, 6, e705. [Google Scholar] [CrossRef] [PubMed]
- Julien, L.; Michel, R.P.; Auger, M. Breast implant–associated anaplastic large cell lymphoma and effusions: A review with emphasis on the role of cytopathology. Cancer Cytopathol. 2020, 128, 440–451. [Google Scholar] [CrossRef] [PubMed]
- Cozzolino, I.; Vitagliano, G.; Caputo, A.; Montella, M.; Franco, R.; Ciancia, G.; Selleri, C.; Zeppa, P. CD15, CD30, and PAX5 evaluation in Hodgkin’s lymphoma on fine-needle aspiration cytology samples. Diagn Cytopathol. 2020, 48, 211–216. [Google Scholar] [CrossRef]
- Takeda, S.; Miyoshi, S.; Ohta, M.; Minami, M.; Masaoka, A.; Matsuda, H. Primary germ cell tumors in the mediastinum. Cancer 2003, 97, 367–376. [Google Scholar] [CrossRef]
- Low, J.J.H.; Ilancheran, A.; Ng, J.S. Malignant ovarian germ-cell tumours. Best Pract. Res. Clin. Obs. Gynaecol. 2012, 26, 347–355. [Google Scholar] [CrossRef] [Green Version]
- Pectasides, D.; Pectasides, E.; Kassanos, D. Germ cell tumors of the ovary. Cancer Treat. Rev. 2008, 34, 427–441. [Google Scholar] [CrossRef] [PubMed]
- Hoei-Hansen, C.E.; Kraggerud, S.M.; Abeler, V.M.; Kærn, J.; Rajpert-De Meyts, E.; Lothe, R.A. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol. Cancer 2007, 6, 12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lifschitz-Mercer, B.; Walt, H.; Kushnir, I.; Jacob, N.; Diener, P.A.; Moll, R.; Czernobilsky, B. Differentiation potential of ovarian dysgerminoma: An immunohistochemical study of 15 cases. Hum. Pathol. 1995, 26, 62–66. Available online: https://www.sciencedirect.com/science/article/pii/0046817795901159 (accessed on 19 May 2023). [CrossRef]
- Bayle, C.; Charpentier, A.; Duchayne, E.; Manel, A.M.; Pages, M.P.; Robert, A.; Lamant, L.; Dastugue, N.; Bertrand, Y.; Dijoud, F.; et al. Leukaemic presentation of small cell variant anaplastic large cell lymphoma: Report of four cases. Br. J. Haematol. 1999, 104, 680–688. [Google Scholar] [CrossRef] [PubMed]
- Falini, B.; Pileri, S.; Zinzani, P.L.; Carbone, A.; Zagonel, V.; Wolf-Peeters, C.; Verhoef, G.; Menestrina, F.; Todeschini, G.; Paulli, M.; et al. ALK+ Lymphoma: Clinico-Pathological Findings and Outcome. Blood 1999, 93, 2697–2706. Available online: https://www.sciencedirect.com/science/article/pii/S0006497120489566 (accessed on 19 May 2023).
- Stein, H.; Foss, H.D.; Dürkop, H.; Marafioti, T.; Delsol, G.; Pulford, K.; Pileri, S.; Falini, B. CD30+ anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 2000, 96, 3681–3695. Available online: https://www.sciencedirect.com/science/article/pii/S0006497120482060 (accessed on 20 May 2023). [CrossRef]
- Falini, B.; Bigerna, B.; Fizzotti, M.; Pulford, K.; Pileri, S.A.; Delsol, G.; Carbone, A.; Paulli, M.; Magrini, U.; Menestrina, F.; et al. ALK Expression Defines a Distinct Group of T/Null Lymphomas (‘ALK Lymphomas’) with a Wide Morphological Spectrum. Am. J. Pathol. 1998, 153, 875–886. [Google Scholar] [CrossRef]
- Kumar, S.; Dispenzieri, A.; Lacy, M.Q.; Hayman, S.R.; Buadi, F.K.; Colby, C.; Laumann, K.; Zeldenrust, S.R.; Leung, N.; Dingli, D.; et al. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. J. Clin. Oncol. 2012, 30, 989–995. [Google Scholar] [CrossRef] [Green Version]
- Pileri, S.A.; Pulford, K.; Mori, S.; Mason, D.Y.; Sabattini, E.; Roncador, G.; Piccioli, M.; Ceccarelli, C.; Piccaluga, P.P.; Santini, D.; et al. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. Am. J. Pathol. 1997, 150, 1207. [Google Scholar] [PubMed]
- Agur, A.; Amir, G.; Paltiel, O.; Klein, M.; Dann, E.J.; Goldschmidt, H.; Goldschmidt, N. CD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma. Leuk. Lymphoma 2015, 56, 1315–1319. [Google Scholar] [CrossRef] [PubMed]
- Isaacson, P.G.; Du, M.Q. MALT lymphoma: From morphology to molecules. Nat. Rev. Cancer 2004, 4, 644–653. [Google Scholar] [CrossRef] [PubMed]
- Hodges, K.B.; Collins, R.D.; Greer, J.P.; Kadin, M.E.; Kinney, M.C. Transformation of the small cell variant Ki-1+ lymphoma to anaplastic large cell lymphoma: Pathologic and clinical features. Am. J. Surg. Pathol. 1999, 23, 49–58. [Google Scholar] [CrossRef] [PubMed]
- Attygalle, A.D.; Cabeçadas, J.; Gaulard, P.; Jaffe, E.S.; de Jong, D.; Ko, Y.H.; Said, J.; Klapper, W. Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward–report on the lymphoma workshop of the XVI th meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology 2014, 64, 171–199. [Google Scholar] [CrossRef]
- Bekkenk, M.W.; Geelen, F.A.M.J.; van Voorst Vader, P.C.; Heule, F.; Geerts, M.L.; van Vloten, W.A.; Meijer, C.J.; Willemze, R. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000, 95, 3653–3661. [Google Scholar] [CrossRef]
- Pittaluga, S.; Wlodarska, I.; Pulford, K.; Campo, E.; Morris, S.W.; Van den Berghe, H.; De Wolf-Peeters, C. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am. J. Pathol. 1997, 151, 343. [Google Scholar]
- Shiota, M.; Nakamura, S.; Ichinohasama, R.; Abe, M.; Akagi, T.; Takeshita, M.; Mori, N.; Fujimoto, J.; Miyauchi, J.; Mikata, A.; et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood 1995, 86, 1954–1960. [Google Scholar] [CrossRef] [Green Version]
- Tardío, J.C.; Granados, R. Axillary lymphadenopathy: An outstanding presentation for breast implant–associated ALK-negative anaplastic large cell lymphoma. Int. J. Surg. Pathol. 2015, 23, 424–428. [Google Scholar] [CrossRef]
- Lee, J.H. Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). Yeungnam Univ. J. Med. 2021, 38, 175–182. [Google Scholar] [CrossRef]
- Edinger, J.T.; Clark, B.Z.; Pucevich, B.E.; Geskin, L.J.; Swerdlow, S.H. CD30 expression and proliferative fraction in non-transformed mycosis fungoides. Am. J. Surg. Pathol. 2009, 33, 1860. [Google Scholar] [CrossRef] [Green Version]
- Arulogun, S.O.; Prince, H.M.; Ng, J.; Lade, S.; Ryan, G.F.; Blewitt, O.; McCormack, C. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 2008, 112, 3082–3087. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- de Coninck, E.C.; Kim, Y.H.; Varghese, A.; Hoppe, R.T. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J. Clin. Oncol. 2001, 19, 779–784. [Google Scholar] [CrossRef] [PubMed]
- Gomez Venegas, A.A.; Vargas Rubio, R.D. Unusual involvement in mycosis fungoides: Duodenal papilla. Rev. Esp. Enferm. Dig. 2016, 108, 513–516. [Google Scholar] [CrossRef] [Green Version]
- Massone, C.; Kodama, K.; Kerl, H.; Cerroni, L. Histopathologic features of early (patch) lesions of mycosis fungoides: A morphologic study on 745 biopsy specimens from 427 patients. Am. J. Surg. Pathol. 2005, 29, 550–560. [Google Scholar] [CrossRef]
- Cerroni, L.; Rieger, E.; Hödl, S.; Kerl, H. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am. J. Surg. Pathol. 1992, 16, 543–552. [Google Scholar] [CrossRef] [PubMed]
- Olsen, E.; Vonderheid, E.; Pimpinelli, N.; Willemze, R.; Kim, Y.; Knobler, R.; Zackheim, H.; Duvic, M.; Estrach, T.; Lamberg, S.; et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110, 1713–1722. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Francisco, J.A.; Cerveny, C.G.; Meyer, D.L.; Mixan, B.J.; Klussman, K.; Chace, D.F.; Rejniak, S.X.; Gordon, K.A.; DeBlanc, R.; Toki, B.E.; et al. cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102, 1458–1465. [Google Scholar] [CrossRef] [Green Version]
- Senter, P.D.; Sievers, E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 2012, 30, 631–637. [Google Scholar] [CrossRef]
- Mei, M.; Thomas, S.; Chen, R. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: Focus on brentuximab vedotin. BioDrugs 2014, 28, 245–251. [Google Scholar] [CrossRef]
- Okeley, N.M.; Miyamoto, J.B.; Zhang, X.; Sanderson, R.J.; Benjamin, D.R.; Sievers, E.L.; Senter, P.D.; Alley, S.C. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug ConjugateReleased Drug from SGN-35. Clin. Cancer Res. 2010, 16, 888–897. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moskowitz, C.H.; Nademanee, A.; Masszi, T.; Agura, E.; Holowiecki, J.; Abidi, M.H.; Chen, A.I.; Stiff, P.; Gianni, A.M.; Carella, A.; et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015, 385, 1853–1862. [Google Scholar] [CrossRef] [PubMed]
- Younes, A.; Gopal, A.K.; Smith, S.E.; Ansell, S.M.; Rosenblatt, J.D.; Savage, K.J.; Ramchandren, R.; Bartlett, N.L.; Cheson, B.D.; de Vos, S.; et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 2012, 30, 2183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zinzani, P.L.; Pellegrini, C.; Cantonetti, M.; Re, A.; Pinto, A.; Pavone, V.; Rigacci, L.; Celli, M.; Broccoli, A.; Argnani, L.; et al. Brentuximab vedotin in transplant-naïve relapsed/refractory Hodgkin lymphoma: Experience in 30 patients. Oncologist 2015, 20, 1413–1416. [Google Scholar] [CrossRef] [Green Version]
- Carlo-Stella, C.; Ricci, F.; Dalto, S.; Mazza, R.; Malagola, M.; Patriarca, F.; Viviani, S.; Russo, D.; Giordano, L.; Castagna, L.; et al. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: Results from a named patient program at four Italian centers. Oncologist 2015, 20, 323–328. [Google Scholar] [CrossRef] [Green Version]
- Kerbauy, L.N.; Marin, N.D.; Kaplan, M.; Banerjee, P.P.; Berrien-Elliott, M.M.; Becker-Hapak, M.; Basar, R.; Foster, M.; Garcia Melo, L.; Neal, C.C.; et al. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ MalignanciesAFM13-Loaded NK Cells as Therapy for CD30+ Tumors. Clin. Cancer Res. 2021, 27, 3744–3756. [Google Scholar] [CrossRef]
- Hogan, L.E.; Vasquez, J.; Hobbs, K.S.; Hanhauser, E.; Aguilar-Rodriguez, B.; Hussien, R.; Thanh, C.; Gibson, E.A.; Carvidi, A.B.; Smith, L.C.B.; et al. Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLoS Pathog. 2018, 14, e1006856. [Google Scholar] [CrossRef]
- Hombach, A.; Jung, W.; Pohl, C.; Renner, C.; Sahin, U.; Schmits, R.; Wolf, J.; Kapp, U.; Diehl, V.; Pfreundschuh, M. A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin’s cells by unstimulated natural killer cells In AND In vivo. Int. J. Cancer 1993, 55, 830–836. [Google Scholar] [CrossRef]
Clinical Symptoms (Skin, Lymph Nodes, Internal Organs) | Histopathology | Immunohistochemistry | ||
---|---|---|---|---|
Lymphomas that affect the thymus (T-cell, B-cell lineages and Hodgkin lymphomas) | Nodular Sclerosis (NS) (subtype of Hodgkin lymphomas—cHLs) |
|
| CD30 + (85–96%, Memb + Golgi area) CD15 + (75–85%) CD20 + (<20–40%) CD79a (Rarely+) PAX5; OCT2; MUM1; EBER (EBV); LMP-1 (EBV) Cyclin E Fascin |
PMBL (primary mediastinal B-cell lymphoma) |
| bulky, solid masses of >10 cm, with local symptoms of rapid growth, invasion, and compression of vital structures. Neoplastic cells
| CD30 + (weakly or focally expressed, with lesser intensity than in cHL) CD45 CD20 CD79a PAX5; OCT2; BOB1; MUM1 MAL; CD23; BCL6; P63 | |
T-lymphoblastic lymphoma (T-Lb) |
|
| CD30 (rare) T-cell markers: CD3, CD5, and CD7 TdT CD1a; CD99; CD4 and CD8; cyclin-dependent kinase-6 (CDK6) | |
B1—Thymoma |
|
| (+) in >90%: CK5/6, CK7, CK8, CK18, CK19, p63 (+) in 50–90%: CD15, CD57 (leu7), PAX-8 Cytokeratins, CD30 | |
ALCL | Anaplastic large cell lymphoma, ALK positive |
|
| (+) in >90% ALK, CD30, clusterin, CD43, cytotoxic molecules (TIA-1, perforin, granzyme B) (+) in 50–90% CD2, CD4, CD25, CD45, EMA, galectin-3 (+) in 10–50% CD3, CD5, CD7, CD15, fascin, bcl-6 (+) in <10% CD8, CD20, CD28, PAX-5 |
Anaplastic large cell lymphoma, ALK negative |
|
| (+) in >90% CD30, clusterin, CD43, cytotoxic molecules (TIA-1, perforin, granzyme B) (+) in 50–90% CD2, CD4, CD25, CD45, EMA, galectin-3 (+) in 10–50% CD3, CD5, CD7, CD15, fascin, bcl-6 (+) in <10% ALK, CD8, CD20, CD28, PAX-5 | |
Mycosis fungoides |
|
| (+) in >90% CD2, CD3, CD5, CD4, CD45RO (+) in 10–50% CD7. CD30 (+) in <10% CD8, CD25 |
Brentuximab Vedotin’s Function in Various Lymphomas | |
---|---|
Classical Hodgkin lymphoma |
|
ALCL |
|
Mycosis Fungoides |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dumitru, A.V.; Țăpoi, D.A.; Halcu, G.; Munteanu, O.; Dumitrascu, D.-I.; Ceaușu, M.C.; Gheorghișan-Gălățeanu, A.-A. The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment. Cells 2023, 12, 1783. https://doi.org/10.3390/cells12131783
Dumitru AV, Țăpoi DA, Halcu G, Munteanu O, Dumitrascu D-I, Ceaușu MC, Gheorghișan-Gălățeanu A-A. The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment. Cells. 2023; 12(13):1783. https://doi.org/10.3390/cells12131783
Chicago/Turabian StyleDumitru, Adrian Vasile, Dana Antonia Țăpoi, Georgian Halcu, Octavian Munteanu, David-Ioan Dumitrascu, Mihail Constantin Ceaușu, and Ancuța-Augustina Gheorghișan-Gălățeanu. 2023. "The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment" Cells 12, no. 13: 1783. https://doi.org/10.3390/cells12131783